RxDoctor Payments DataLook up a doctor →

Salma Saiger, MD

Internal Medicine · Mesquite, TXNPI 1487690855

Payments from drug & device makers

$16,101,628in general payments, 2019–2025

Across 1,683 payments — averaging $9567.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$10.2M
  • Partner Therapeutics, Inc.$1.1M
  • Janssen Research & Development, LLC$806K
  • Sanofi US Services Inc.$703K
  • Bavarian Nordic A/s$673K
  • GSK$511K
  • plus $2.1M from 48 others
$39,156in research payments, 2019–2025

Across 21 payments — averaging $1864.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • First Wave Biopharma, Inc.$37K
  • Sanofi US Services Inc.$2K
  • Eli Lilly$481

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer551$10,183,926
Partner Therapeutics, Inc.12$1,114,370
Janssen Research & Development, LLC117$805,989
Sanofi US Services Inc.75$703,439
Bavarian Nordic A/s59$673,160
GSK128$510,677
Genentech, Inc.45$510,506
Amgen32$352,641
Cleerly, Inc.37$344,528
Astrazeneca UK Limited2$220,464
Abbott124$212,705
Boehringer Ingelheim27$60,387
AbbVie(2 entities)56$58,824
Tolmar, Inc.36$53,900
Sun Pharmaceutical Industries Inc.4$41,837
AstraZeneca62$38,880
Ionis Pharmaceuticals, Inc.17$31,841
Bausch Health US, LLC14$30,314
Romark Laboratories, LC1$29,738
Insmed, Inc.13$29,402
F. Hoffmann-la Roche AG5$23,298
First Wave Biopharma, Inc.1$20,144
Biohaven Pharmaceutical Holding Company Ltd.2$18,000
Chiesi USA, Inc.1$10,000
Vanda Pharmaceuticals Inc.4$7,750
Teva Pharmaceuticals USA, Inc.17$6,167
Modernatx, Inc.8$5,068
Novo Nordisk59$931
Merck44$549
Lilly USA, LLC32$509
Amarin Pharma, Inc.23$376
Bayer22$355
Johnson & Johnson9$131
Corcept Therapeutics3$113
Ironwood Pharmaceuticals, Inc5$82
Sanofi-aventis U.S. LLC5$80
Otsuka America Pharmaceutical, Inc.2$54
Dexcom, Inc.3$52
Exact Sciences3$50
Astellas Pharma US Inc3$49
Novartis2$41
Currax Pharmaceuticals LLC3$37
Nestle Healthcare Nutrition Inc.2$35
Sunovion Pharmaceuticals Inc.2$29
Genentech USA, Inc.2$28
Sanofi1$28
Idorsia Pharmaceuticals US Inc1$20
Shield Therapeutics Inc1$20
Esperion Therapeutics, Inc.1$20
Stryker1$19
Phathom Pharmaceuticals, Inc.1$18
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC1$17
Optos, Inc.1$15
Mylan Specialty L.p.1$15

How this compares

$16,101,628 in reported general payments places this provider in the 95th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas →

Medicare billing

Part B allowed, 2024
$123,666
Medicare patients
153
Services billed
2,107

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Mesquite

See the full list for Texas →

Where these figures come from

Is this you, or does something look wrong? →